A Phase 1 interventional study of TolaSure Topical Gel and Vehicle Topical Gel in Epidermolysis Bullosa Simplex, sponsored by BioMendics, LLC. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-11.
Sponsored by BioMendics, LLC · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Epidermolysis Bullosa Simplex with a site in United States — 3 open to participants now, 4 under way, 1 of them phase 3. Epidermolysis Bullosa Simplex · United States.
Among the 11 studies in Epidermolysis Bullosa Simplex with a site in United States, this one is the only one that started in 2022, is one of 3 in phase 1, and was the 8th registered.
20 studies on the registry are indexed under Epidermolysis Bullosa Simplex; 5 are open to participants now.
Browse Epidermolysis Bullosa Simplex studies →3 of the 11 studies in Epidermolysis Bullosa Simplex with a site in United States are open now. Recruiting first, the newest first:
BioMendics, LLC · Sites in United States
Ages 2+
Joyce Teng · Sites in United States
Ages 0+ · Healthy volunteers
Stanford University · Sites in United States
Ages 6 mo+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 4 Epidermolysis Bullosa Simplex studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 1
First in 2015; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 6 is below the median of 19 across 17 interventional studies indexed under Epidermolysis Bullosa Simplex.
Median enrollment 11 across the 9 interventional studies, 30 across the 2 observational. Of the 6 that completed or were terminated, 4 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 11 have an industry lead sponsor. The 7 most frequent:
BioMendics, LLC is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
BioMendics, LLC has 2 studies filed under Epidermolysis Bullosa Simplex — fewer than ten, so there is no comparison to draw.
2 of the studies in Epidermolysis Bullosa Simplex with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07027345BioMendics, LLCA Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex | 2027-01 |
| NCT07756138Stanford UniversityFilsuvez in Moderate-to-Severe Epidermolysis Bullosa Simplex | 2027-01-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies in Epidermolysis Bullosa Simplex with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
TolaSure is a topical gel for the promotion of accelerated wound healing. This Phase I study will assess the safety, tolerability, and clinical effects of TolaSure when applied to wounded skin areas of patients diagnosed with severe epidermolysis bullosa simplex (i.e., EBS-Dowling Meara). A total of 10, severe EBS patients, males and females ages 18 years and older, will be enrolled. Patients will apply TolaSure and Vehicle Gel once-daily for a maximum of 10 weeks.
This is a closed-label, randomized, double-blind, Phase I clinical study to assess the safety and tolerability of the investigational product (IP), TolaSure Gel, 5% w/w, in patients diagnosed with severe epidermolysis bullosa simplex (EBS, previously known as EBS-Dowling Meara). Each patient (5 to complete) will apply TolaSure Gel, 5% w/w and TolaSure Vehicle Gel once-daily to defined Treatment Areas and Suction Blister Areas. End of Study (EOS) will occur at the Principal Investigator's (PI's) discretion according to the resolution or lack of improvement of the Treatment Areas. The maximum time a patient could be in the study is 10 weeks. The average time frame for each patient to complete the study is expected to be 6-8 weeks.
The primary safety endpoint will be the incidence of treatment-emergent adverse events (TEAEs). Safety monitoring will include physical exams, vital sign measurements, clinical laboratory testing (blood and urinalysis), and urine pregnancy testing (as appropriate).
Secondary efficacy endpoints will (1) assess wound severity within the Treatment Areas using an Investigator Global Assessment (IGA) scoring system, (2) examine under a microscope keratinocyte morphology and the incidence of keratin aggregates in Treatment Area skin biopsies, (3) determine the time required to induce a suction blister within the designated Suction Blister Areas, and (4) evaluate patient self-assessment of overall impression, pain, and itch within the Treatment Areas. The information obtained from these assessments will be used to examine the efficacy of TolaSure treatment in improving EBS symptoms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient possesses the four required skin areas:
Treatment Areas:
Suction Blister Areas (SBAs):
If the patient is a woman of (WOCBP),
Exclusion Criteria:
Patient's use of prior or concomitant medication or medical treatments/procedures:
Patient's medical history includes:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
5% (w/w) TolaSure Gel
Drug: TolaSure Topical Gel
TolaSure Vehicle Gel
Drug: Vehicle Topical Gel
TolaSure Topical Gel is applied once-daily for up to 10 weeks to designated Treatment Area and Suction Blister Area.
Also known as: Active Ingredient BM-3103
TolaSure Vehicle Gel is applied once-daily for up to 10 weeks to designated Treatment Area and Suction Blister Area.
Also known as: TolaSure Vehicle Gel
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Safety monitoring will include clinical chemistry tests, physical examinations (including assessment of Treatment and Suction Blister Areas), and vital sign measurements. These assessments along with AE reviews will identify potential TEAEs.
Time frame: Day 1, Day 2, then Weekly until End of Study (maximum 10 weeks)
Investigator Global Assessment (IGA)
The Principal Investigator will use the IGA scale to score the average overall severity of the EBS wounds within the Treatment Areas, considered together. Changes from baseline in IGA scores for the TolaSure-treated and Vehicle-treated Treatment Areas will be analyzed.
Time frame: Day 1, Day 2, then Weekly until End of Study (maximum 10 weeks)
Keratin Aggregate Counts and Cell Morphology Assessment
Biopsies from perilesional skin in each of the Treatment Areas are examined to determine a change from baseline in the number of keratin aggregate positive basal and suprabasal keratinocytes using transmission electron microscopy (TEM) and/or light microscopy.
Time frame: Day 1, During Study (optional, estimated Week 3-Week 6), End of Study (maximum 10 weeks)
Suction Blister Time
A suction blister is raised within the Suction Blister Areas and the time to blister formation is recorded in seconds. Changes from baseline suction blister times in the TolaSure-treated and Vehicle-treated Suction Blister Areas will be analyzed.
Time frame: Day 1 and End of Study (maximum 10 weeks)
Patient's-reported Overall Impression Score of Treatment Areas
Change from baseline in the patient-reported overall impression score of both the TolaSure-treated and Vehicle-treated Treatment Areas will be calculated.
Time frame: Day 1, then Weekly until End of Study (maximum 10 weeks)
Patient's-reported Pain Score of Treatment Areas
Change from baseline in the patient-reported pain numerical rating scale (NRS) of both the TolaSure-treated and Vehicle-treated Treatment Areas will be calculated.
Time frame: Day 1, then Weekly until End of Study (maximum 10 weeks)
Patient's-reported Itch Score of Treatment Areas
Change from baseline in the patient-reported itch numerical rating scale (NRS) of both the TolaSure-treated and Vehicle-treated Treatment Areas will be calculated.
Time frame: Day 1, then Weekly until End of Study (maximum 10 weeks)
Proportion of Keratinocytes containing Autophagosomes
Biopsies from perilesional skin in each of the Treatment Areas are examined to determine a change from baseline in the number of autophagosome positive basal and suprabasal keratinocytes using transmission electron microscopy (TEM) and/or light microscopy.
Time frame: Day 1, During Study (optional, estimated Week 3-Week 6), End of Study (maximum 10 weeks)
Cytokine Content in Suction Blister Fluid
Suction blister fluid collected from each of the induced suction blisters will be used to determine a change from baseline in inflammatory cytokine content.
Time frame: Day 1 and End of Study (maximum 10 weeks)
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2022 to primary completion in Jun 2023, 13 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Epidermolysis Bullosa Simplex →
BioMendics, LLC